MedTrace Logo

Unrelated Donor Transplant for Malignant and Non-Malignant Disorders

NCT01050439 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2015-04-15

No results posted yet for this study

Summary

Unrelated matched donor (cord blood, bone marrow or peripheral blood) allogeneic stem cell transplantation (UDAlloSCT) with either myeloablative or reduced intensity conditioning will be well tolerated and result in a high degree of engraftment in patients with selected malignant and non malignant disorders.

Conditions

  • Leukemia
  • Lymphoma
  • Bone Marrow Failure Syndromes
  • Immunodeficiencies
  • Histiocytosis

Interventions

PROCEDURE

UDAlloSCT

unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT)

OTHER

Therapy

Full Intensity Therapy (myeloablative) (TBI + Thiotepa + Cyc) OR Reduced Intensity Therapy (Fludarabine, Busulfan, and Alemutuzumab (FBA))

Sponsors & Collaborators

Principal Investigators

  • Mitchell S Cairo, MD · Columbia University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01050439 on ClinicalTrials.gov